<p>Dynamic Changes of Blood Lipids in Breast Cancer Patients After (Neo)adjuvant Chemotherapy: A Retrospective Observational Study</p>

Abstract

Background: Previous studies indicated that the (neo)adjuvant chemotherapy for breast cancer can cause significant dyslipidemia in patients, but how long this abnormality can persist is unclear so far. The purpose of this study is to investigate whether (neo)adjuvant chemotherapy has a long-term effect on blood lipids in breast cancer patients. Methods: A total of 159 newly diagnosed female breast cancer patients receiving the (neo) adjuvant chemotherapy subsequently and 159 female healthy controls were enrolled into the observational study. All participants' blood lipid profiles which included TC, TG, HDL-C, and LDL-C before and at the end of the 1st and 12th month after chemotherapy were retrieved from the electronic medical record system. The blood lipid profiles and the percentage of dyslipidemia before and after chemotherapy in breast cancer patients and controls were compared. Results: Compared with the baseline before chemotherapy, TC, LDL-C, and TG increased significantly at the end of the 1st month after chemotherapy, but only the abnormal increase in TG (2.98±0.71 mmol/L vs 2.82±0.63 mmol/L, P<0.05) and LDL-C (1.82±0.42 mmol/L vs 1.59±0.42 mmol/L, P<0.05) continued until the 12th month after chemotherapy. Levels of HDL-C in breast cancer patients and all the blood lipid parameters in controls remained stable during the observation period. The percentage of dyslipidemia in breast cancer patients rose from 41.5% at baseline to 54.1% at the 12th month after chemotherapy. Subgroup analysis demonstrated that the increase in dyslipidemia percentage was more pronounced in patients with low body mass index and aged over 50 years. Conclusion: The (neo)adjuvant chemotherapy used for treating breast cancers can cause significant abnormalities in blood lipid profiles, and the abnormal increase in LDL-C and TG can last at least 12 months after chemotherapy, which indicates long-term management of blood lipid is necessary for those patients.

Alantolactone: A Natural Plant Extract as a Potential Therapeutic Agent for Cancer

“…Breast cancer is a common cancer in women (Liu Y. et al, 2020;Wan et al, 2020). Although the diagnosis strategies like the mammogram, have been developed in recent years, the mortality rate of breast cancer is still high (Ranjkesh et al, 2020;Xu et al, 2020). As a result, innovative alternatives are needed to improve the therapeutic outcome of patients with breast cancer Studies have shown that ALT changes the cell morphology and decreases the cell viability of MDA-MB-231 and MCF-7 breast cancer cells (Liu J. et al, 2018;Cui et al, 2018).…”

Beneficial Effects of Oral Nutritional Supplements on Body Composition and Biochemical Parameters in Women with Breast Cancer Undergoing Postoperative Chemotherapy: A Propensity Score Matching Analysis

“…The observed disturbances may result from the influence of cytostatics on the expression of enzymes involved in lipid metabolisms such as lipoprotein lipase and lecithin cholesterol acyltransferase. Dyslipidemia is an unfavorable prognostic factor [74,75], since it leads to the development of cardiovascular disease, which is the leading cause of death in people recovering from breast cancer [23]. Our study revealed that ONS maintains a constant triglyceride level and HDL cholesterol in women with normal initial adipose tissue content during chemotherapy.…”

“…These changes are associated with poor clinical outcomes, including lower disease-free and progression-free survival and higher overall mortality [18][19][20][21]. The immediate rise in total cholesterol, LDL cholesterol, and triglycerides levels during chemotherapy in patients with breast cancer has almost become an indisputable fact [12,22,23]. Recent studies have indicated that dyslipidemia does not diminish rapidly after chemotherapy [23].…”

“…The immediate rise in total cholesterol, LDL cholesterol, and triglycerides levels during chemotherapy in patients with breast cancer has almost become an indisputable fact [12,22,23]. Recent studies have indicated that dyslipidemia does not diminish rapidly after chemotherapy [23]. Persistent dyslipidemia among patients with breast cancer may significantly increase the risk for the development of comorbidities and long-term survival [23].…”

“…Recent studies have indicated that dyslipidemia does not diminish rapidly after chemotherapy [23]. Persistent dyslipidemia among patients with breast cancer may significantly increase the risk for the development of comorbidities and long-term survival [23]. In addition, patients receiving chemotherapy are exposed to a decrease in albumin, which is associated with a higher incidence of severe symptoms of chemotherapy-induced toxicity [24].…”